Document is current
Any future updates will be listed below
-
Authors
Huang, Yongbo
Lin, Zhimin
Guo, Xueyan
Zhang, Fangfang
Wang, Yanqun
Zhang, Zhaoyong
Chen, Jiantao
Liu, Lu
Zhu, Mengzhu
Li, Yiting
Ni, Meng
Zhen, Zixian
Wu, Zhihai
Ling, Xiaomin
Zhou, Shuaixiang
Xi, Yin
Yu, Yuheng
Liang, Wenhua
Zhao, Jincun
Li, Li
He, Jianxing
Sang, Ling
-
Funding
Funding for this research was provided by:
National Key R&D Program of China (2022YFC2504402)
Emergency Key Program of Guangzhou Laboratory (EKPG21-17)
National Natural Science Foundation of China (82270081)
Natural Science Foundation of Guangdong Province (2020A1515011459)
- License Information
-
More Information
Article History
Received: 26 March 2025
Accepted: 27 September 2025
First Online: 4 November 2025
Declarations
:
: Not applicable.
: Not applicable.
: All authors affiliated with Innovent Biologics are employees of Innovent Biologics (Suzhou), who is commencing the commercialization of IBI314. The other authors declare no competing interests.
